- Case 9-2012: A 67-Year-Old Man with a Persistently Elevated PSA Level
[作者：Kaufman, DS; Zietman, AL; McDougal, WS; Dahl, DM; Harisinghani, MG; Wu, CL,期刊：New England Journal of Medicine, 页码：1143-1150 , 文章类型： Article，,卷期：2012年366-12]
-
- Clonal Architecture of Secondary Acute Myeloid Leukemia
[作者：Walter, MJ; Shen, D; Ding, L; Shao, J; Koboldt, DC; Chen, K; Larson, DE; McLellan, MD; Dooling, D; Abbott, R; Fulton, R; Magrini, V; Schmidt, H; Kalicki-Veizer, J; O'Laughlin, M; Fan, X; Grillot, M; Witowski, S; Heath, S; Frater, JL; Eades, W; Tomasson, M; Westervelt, P; DiPersio, JF; Link, DC; Mardis, ER; Ley, TJ; Wilson, RK; Graubert, TA,期刊：New England Journal of Medicine, 页码：1090-1098 , 文章类型： Article，,卷期：2012年366-12]
- BACKGROUND The myelodysplastic syndromes are a group of hematologic disorders that often evolve into secondary acute myeloid leukemia (AML). The genetic changes that underlie progression from the myelodysplastic syndrome...
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
[作者：Patel, JP; Gonen, M; Figueroa, ME; Fernandez, H; Sun, ZX; Racevskis, J; Van Vlierberghe, P; Dolgalev, I; Thomas, S; Aminova, O; Huberman, K; Cheng, J; Viale, A; Socci, ND; Heguy, A; Cherry, A; Vance, G; Higgins, RR; Ketterling, RP; Gallagher, RE; Litzow, M; van den Brink, MRM; Lazarus, HM; Rowe, JM; Luger, S; Ferrando, A; Paietta, E; Tallman, MS; Melnick, A; Abdel-Wahab, O; Levine, RL,期刊：New England Journal of Medicine, 页码：1079-1089 , 文章类型： Article，,卷期：2012年366-12]
- BACKGROUND Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated in...
- A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
[作者：Parsons, M; Spratt, N; Bivard, A; Campbell, B; Chung, K; Miteff, F; O'Brien, B; Bladin, C; McElduff, P; Allen, C; Bateman, G; Donnan, G; Davis, S; Levi, C,期刊：New England Journal of Medicine, 页码：1099-1107 , 文章类型： Article，,卷期：2012年366-12]
- BACKGROUND Intravenous alteplase is the only approved treatment for acute ischemic stroke. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, is an alternative thrombolytic agent. METHODS In this...
|